Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Breast 2 Tumor-Agnostic 1 Gynecologic 1 Genitourinary 1

Conditions

Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 182 Magnetic Resonance Spectroscopy 163 Specimen Handling 135 enzalutamide 126 Nivolumab 124 Gemcitabine 99 Docetaxel 96 Radiosurgery 92 Prednisone 85 Androgen Antagonists 82 Abiraterone Acetate 81 Radiotherapy 75 apalutamide 68 Cisplatin 65 darolutamide 63 Ipilimumab 63 Biopsy 60 abiraterone 58 Carboplatin 56 cabozantinib 55 Leuprolide 53 enfortumab vedotin 49 Radiation 48 Pluvicto 45 Standard of Care 44 atezolizumab 40 Surveys and Questionnaires 39 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37 X-Rays 37 avelumab 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

vistusertib × Genitourinary × 1 year × Clear all

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡